ÍøºìºÚÁÏ

Skip to main content

Jorge E Lascano, MD

Critical Care Specialist

Photo of Jorge E Lascano

Research at a glance

Top areas of exploration

  • alpha 1-Antitrypsin Deficiency , 9 publications
  • Pulmonary Disease, Chronic Obstructive , 8 publications
  • alpha 1-Antitrypsin , 7 publications
  • Cystic Fibrosis , 3 publications

Research activity

44 publications

427 citations

Why is this important?

Active clinical trials

Serpentine-1

The Sponsor is developing KB408, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human SERPINA1 to the airways of people with alpha-1 antitrypsin deficiency…

Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
18 Years - 70 Years
Sexes
All
KB407-02

This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All
ELEVAATE OLE

Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema

Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
18 Years - 80 Years
Sexes
All

My publications

44 publications

2016

Prognostic utility of plasma lactate measured between 24 and 48 h after initiation of early goal-directed therapy in the management of sepsis, severe sepsis, and septic shock.

Journal of intensive care

•

2015

Lactate kinetics in sepsis and septic shock: a review of the literature and rationale for further research.

Journal of intensive care

•

2014

Ivacaftor Therapy in CF Patients: Single Center Experience.

Advances in medicine

•

2014

α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.

Therapeutic advances in respiratory disease

•